SAN FRANCISCO, Oct. 1 Medizone International,Inc. (Pink Sheets: MZEI) announces a new strategic thrust pursuing thedevelopment of a novel ozone-based technology which will offer a safe,inexpensive, extremely effective means of disinfecting medical facilities ofall bacteria, fungi and viruses known to cause hospital-derived infections.Since this technology is not considered a medical treatment or a diagnostic,its developmental pathway will not be subject to regulatory review or therequirement for a lengthy clinical trial process. Medizone Board member andProject Director, Dr. Michael E. Shannon stated, "Our focus with thisinitiative will be on peer reviewed science and engineering excellence.Hospital-derived infections have grown to immense proportions worldwide withseveral recently published studies indicating that the incidence of suchinfections has climbed dramatically over the last ten years in the US with themortality rate more than doubling during the same period despite increasedpublic health efforts to control the situation. At present, there is no knownmeans to effectively eliminate many of the highly virulent bacterialcontaminants now commonly found in critical hospital treatment areas such assurgical suites, emergency rooms and intensive care units. Yet there clearlyappears to be an answer. Based on independent research recently conducted atan internationally-renowned institute, ozone-based technology has been shownto effectively eradicate 99.99% of the 6 most serious bacterial agentsincluding C-difficile and Methecillin-Resistant Staphylococcus Aureus (MRSA)within 90 minutes, with the hospital space almost immediately re-usable usinga second newly-developed technology. In effect, virtually any contaminatedfacility may be fully sterilized and returned to service in 2 hours or less.Such a development should have a monumental impact on health care systemsglobally."
Mr. Edwin Marshall, Chairman and CEO of Medizone International stated,"With Dr. Shannon's leadership in this exciting new initiative, we anticipatebeing fully commercialized within 18 months. The anticipated revenue generatedwill fund advanced efforts in developing bio-terrorism counter-measures, anarea of enormous potential for this technology, as well as funding a new focuson our work in the treatment of Hepatitis C."
Medizone International, Inc., is a research and development stage companyengaged in the development of patented and unpatented technologies andprotocols for O3 based bio-oxidative treatment of diseases caused by lipidenveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS),Hepatitis B & C, and Herpes, the decontamination of blood, blood products andveterinarian serum products, and the treatment of external pathogenicconditions. It is currently developing technology to decontaminate andsterilize hospital surgical suites, emergency rooms and intensive care units.
This Press Release contains certain forward looking statements thatinvolve substantial risks and uncertainties, including, but not limited to,the results of ongoing clinical studies, economic conditions, product andtechnology development, production efficiencies, product demand, competitiveproducts, competitive environment, successful testing and governmentregulatory issues. Additional risks are identified in the company's filingsmade with the Securities and Exchange Commission.Web site: http://www.medizoneint.com Investor Relations 800-953-3350
SOURCE Medizone International, Inc.